InMed Pharmaceuticals (INM) Return on Capital Employed (2022 - 2026)
InMed Pharmaceuticals' (INM) quarterly Return on Capital Employed came in at 110.05% in Q1 2026, up 242.0% year-on-year from 32.18% in Q1 2025, and down 43.16% quarter-over-quarter from 76.87% in Q4 2025.
InMed Pharmaceuticals (INM) Return on Capital Employed (2022 - 2026) Analysis & Trends
InMed Pharmaceuticals' Return on Capital Employed history runs 5 years deep, the most recent figure standing at 110.05% for Q1 2026.
- On a quarterly basis, Return on Capital Employed rose 242.0% year-over-year to 110.05% in Q1 2026; TTM through Mar 2026 was 110.05%, a 242.0% increase from a year earlier, with the FY2025 full-year figure at 66.99%, up 757.0% from the prior year.
- Return on Capital Employed eased to 110.05% in Q1 2026 per INM's latest filing, from 76.87% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 52.02% in Q1 2024 and bottomed at 172.51% in Q3 2022.
- The 5-year median for Return on Capital Employed is 78.09% (2024), against an average of 94.03%.
- Across the five-year window, Return on Capital Employed surged 10517 bps in 2023 and sank 6045 bps in 2025, its largest moves.
- Year by year, Return on Capital Employed stood at 118.71% in 2022, then jumped by 49 bps to 60.98% in 2023, then tumbled by 68 bps to 102.27% in 2024, then advanced by 25 bps to 76.87% in 2025, then plunged by 43 bps to 110.05% in 2026.
- Per Business Quant, the three latest INM Return on Capital Employed figures stand at 110.05% (Q1 2026), 76.87% (Q4 2025), and 65.43% (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 8.52% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 27.36% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -1.50% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 21.43% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 0.46% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 20.04% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 5.24% |
| 10 | InMed Pharmaceuticals | 307,858.50 | -4.93 Mn | - | -110.05% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -110.05% |
| Dec 31, 2025 | -76.87% |
| Sep 30, 2025 | -65.43% |
| Jun 30, 2025 | -78.99% |
| Mar 31, 2025 | -112.47% |
| Dec 31, 2024 | -102.27% |
| Sep 30, 2024 | -74.77% |
| Jun 30, 2024 | -77.19% |
| Mar 31, 2024 | -52.02% |
| Dec 31, 2023 | -60.98% |
| Sep 30, 2023 | -67.34% |
| Jun 30, 2023 | -67.86% |
| Mar 31, 2023 | -106.69% |
| Dec 31, 2022 | -118.71% |
| Sep 30, 2022 | -172.51% |
| Jun 30, 2022 | -160.33% |